These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 15174980)
1. Long-term solutions for the problem of vaccine shortages. Lattanzi M; Rappuoli R Expert Opin Biol Ther; 2004 Jun; 4(6):989-92. PubMed ID: 15174980 [TBL] [Abstract][Full Text] [Related]
2. The Children's Vaccine Initiative and vaccine supply: the role of the public sector. van Noort RB Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410 [TBL] [Abstract][Full Text] [Related]
3. Medicine. The intangible value of vaccination. Rappuoli R; Miller HI; Falkow S Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712 [No Abstract] [Full Text] [Related]
4. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States. Shen AK; Rodewald LE; Birkhead GS Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586 [TBL] [Abstract][Full Text] [Related]
5. Strengthening vaccination policies in Latin America: an evidence-based approach. Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196 [TBL] [Abstract][Full Text] [Related]
6. Costs of vaccine programs across 94 low- and middle-income countries. Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184 [TBL] [Abstract][Full Text] [Related]
7. An evaluation of South Africa's public-private partnership for the localisation of vaccine research, manufacture and distribution. Walwyn DR; Nkolele AT Health Res Policy Syst; 2018 Mar; 16(1):30. PubMed ID: 29587777 [TBL] [Abstract][Full Text] [Related]
8. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. Peny JM; Gleizes O; Covilard JP Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769 [TBL] [Abstract][Full Text] [Related]
9. Paving the way for the introduction of new vaccines into developing countries. Chabalgoity JA Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986 [TBL] [Abstract][Full Text] [Related]
10. Vaccine development and deployment: opportunities and challenges in India. Gupta SS; Nair GB; Arora NK; Ganguly NK Vaccine; 2013 Apr; 31 Suppl 2():B43-53. PubMed ID: 23598492 [TBL] [Abstract][Full Text] [Related]
11. The introduction of new vaccines into developing countries. III. The role of intellectual property. Mahoney RT; Pablos-Mendez A; Ramachandran S Vaccine; 2004 Jan; 22(5-6):786-92. PubMed ID: 14741174 [TBL] [Abstract][Full Text] [Related]
12. Investing in vaccines for developing countries: How public-private partnerships can confront neglected diseases. Yaïch M Hum Vaccin; 2009 Jun; 5(6):368-9. PubMed ID: 19270505 [TBL] [Abstract][Full Text] [Related]
13. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries? Brenzel L Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183 [TBL] [Abstract][Full Text] [Related]
14. Economic aspects of vaccines and immunizations. Hinman AR C R Acad Sci III; 1999 Nov; 322(11):989-94. PubMed ID: 10646095 [TBL] [Abstract][Full Text] [Related]
15. Analytics for vaccine economics and pricing: insights and observations. Robbins MJ; Jacobson SH Expert Rev Vaccines; 2015 Apr; 14(4):605-16. PubMed ID: 25435003 [TBL] [Abstract][Full Text] [Related]
16. Policy analysis: an essential research tool for the introduction of vaccines in developing countries. Mahoney R J Health Popul Nutr; 2004 Sep; 22(3):331-7. PubMed ID: 15609786 [TBL] [Abstract][Full Text] [Related]
17. The U.S. vaccine and immunization enterprise: Working to sustain and foster vaccine innovation. Shen AK Hum Vaccin; 2009 Oct; 5(10):649-53. PubMed ID: 19713758 [TBL] [Abstract][Full Text] [Related]